Treatments and trials that were formally studied and did not demonstrate the benefit they were tested for — recorded because a negative result is real evidence too, not a story to be hidden.
Most research does not lead to a new treatment. A trial can be well-designed, well-run, and still show no meaningful benefit — or real harm — once tested rigorously. This page collects that research on purpose: understanding what did not work is real scientific progress, not a footnote, and hiding it would make the record of cancer research dishonest.
A story appearing here does not mean the underlying biological idea was worthless — only that this specific approach, at this specific stage, did not demonstrate the benefit it was tested for. Evidence stage, regulatory status, and any correction history remain visible on every record here exactly as everywhere else on this site.
A peer-reviewed case series describing three patients who self-administered fenbendazole (a veterinary dewormer, not an approved human cancer drug) alongside their standard cancer treatment, and reported remission, was published in…
Primary source cited
Last reviewed
In the randomized, phase 3 ASCENT-07 trial, sacituzumab govitecan did NOT improve progression-free survival compared with standard-of-care chemotherapy as a first chemotherapy option for hormone-receptor-positive, HER2-negative advanced breast cancer --…
Primary source cited
Last reviewed
A single glioblastoma patient's response to neoadjuvant checkpoint immunotherapy has prompted a formal randomized Phase II trial (GIANT, at Duke University, testing nivolumab with or without relatlimab).
Primary source cited
Last reviewed
CancerDiscoveries summarizes verified records in its database. Absence of a listing here does not establish that a treatment lacks regulatory authorization or access.